EP Patent

EP4613337B1 — Crystalline form of triethylenetetramine tetrahydrochloride for the treatment of wilson's disease

Assigned to Orphalan SA · Expires 2026-04-15 · 0y expired

What this patent protects

Patent listed against trientine-tetrahydrochloride.

Drugs covered by this patent

trientine-tetrahydrochloride (TRIENTINE TETRAHYDROCHLORIDE)

Patent Metadata

Patent number: EP4613337B1
Jurisdiction: EP
Classification: —
Expires: 2026-04-15
Drug substance claim: No
Drug product claim: No
Assignee: Orphalan SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.